Hydralazine Hydrochloride, marketed under the trade name Dralzine®, is an antihypertensive medication that has been approved since 1952 for the treatment of hypertension. Developed by Novartis, Hydralazine Hydrochloride works as AOC3 inhibitors, aiding in the management of essential hypertension, severe hypertension, heart failure, pre-eclampsia, and eclampsia. Its mechanism of action has made it a reliable option for individuals requiring immediate action for hypertension. As a trusted medication in the field of hypertension treatment, Hydralazine Hydrochloride has helped countless individuals manage their blood pressure and maintain healthy lifestyles. Click on the image below to begin the exploration journey of Hydralazine through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!